Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FPR1 | P21462 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19469601 | 0.90 | CFTR (0.48) | CFTRCYP19A1GABRA1TMEM97SIGMAR1 | |
| Hydrochloric Acid SCHEMBL20957902 | 0.89 | CFTR (0.47) | CFTRCYP19A1GABRA1TMEM97SIGMAR1 | |
| SCHEMBL17708692 | 0.85 | CFTR (0.45) | CFTRKMT2AMEN1CYP19A1LMNA | |
| SCHEMBL17709125 | 0.84 | ESR1 (0.47) | CFTRKMT2AMEN1CYP19A1 | |
| SCHEMBL17709193 | 0.84 | LOXL2 (0.38) | CFTRKMT2AMEN1KDM4E | |
| SCHEMBL17709088 | 0.84 | RAB9A (0.43) | CFTRKMT2AMEN1MAPT | |
| SCHEMBL28649033 | 0.84 | RAB9A (0.43) | CFTRKMT2AMEN1MAPT | |
| Hydrochloric Acid SCHEMBL19469636 | 0.83 | RAB9A (0.43) | CFTRKMT2AMEN1MAPTKDM4E | |
| SCHEMBL17709034 | 0.83 | CFTR (0.47) | CFTRKMT2AATMLMNAKDM4E | |
| SCHEMBL17709076 | 0.82 | CFTR (0.49) | CFTRCYP19A1KDM4EGABRA1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107405337-B | Substituted chromans and methods of use | 艾伯维公司 | 2021-02-09 | — | — | CN | disclosed |
| EP-3212189-B1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE OVERSEAS SÀ RL (LU) | 2020-09-09 | — | — | EP | disclosed |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2019-05-02 | — | — | US | disclosed |
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE S À R L (LU) | 2017-07-06 | — | — | US | disclosed |
| US-9642831-B2 | Substituted chromanes and method of use | ABBVIE S.Á.R.L. (LU) | 2017-05-09 | — | — | US | disclosed |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE GLOBAL LIMITED (BM) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | CFTR 1/4885KMT2A 4725/4885MEN1 1408/4885 |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | CFTR 1/4885KMT2A 4725/4885MEN1 1408/4885 |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | CFTR, CHRM3, CHRM2 | CFTR 1/4885KMT2A 4725/4885MEN1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.